inapparently infect blood donors. To assess transfusion transmission of HEV in the United States, which has not been documented, a donor-recipient repository was evaluated.
commonly acquired by enteric transmission and, in developing countries, genotypes 1 and 2 can cause large waterborne epidemics associated with monsoon rain or humanitarian emergencies with contaminated supplies of drinking water. More recently, autochthonous HEV infections have been reported frequently among populations in industrialized countries. Such infections are associated with genotype 3 or 4, and usually occur as isolated cases or in small clusters. They commonly include asymptomatic infections of adults who acquire HEV from contaminated food, especially solid-organ meats from swine, wild boar, deer, or raw shellfish.
HEV transmission by transfusion has been reported since 2004 from Europe and Japan. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] A study of 225,000
southeastern UK donors identified 79 (0.035%) with detectable HEV RNA. 8 Among 43 patients who were transfused with these donors' HEV RNA-containing products, 18 (42%) became infected. Chinese, European, and American investigators have detected HEV RNA in blood products, including pooled plasma, from otherwise acceptable donors. 6, [13] [14] [15] [16] [17] In
Japan, a total of 20 patients were reported to have acquired HEV by transfusion of blood products. 12 Consequently, blood centers in Hokkaido prefecture of northern Japan have routinely screened donors for HEV RNA during the past 10 years to prevent transmission by transfusion. 11, 12 Despite these international reports, limited data have been reported from blood centers in the United States. A study of 1939 donors at the National Institutes of Health Clinical Center (NIH CC, Bethesda, MD), who were sampled in 2006 and 2012, found 18.8% with IgG anti-HEV and 0.4% with IgM anti-HEV but none had detectable HEV RNA. 18 A study of 18,829 American Red Cross (ARC) donation samples, collected during 2013, identified 2 (0.01%) with HEV RNA, 7.7% with IgG anti-HEV, and 0.58% with IgM anti-HEV. 16 Another study of ARC donors, 5040 who were sampled in 2015, detected IgG anti-HEV among 11.4%; 0.18% had IgM anti-HEV detected by each of three assays, among which there was only 22% agreement. 19 HEV transmission in these US studies could not be assessed, however, because donations were not linked to blood product recipients.
To evaluate the risk of HEV transmission by transfusion in a US population, we tested samples from the Retrovirus Epidemiology Donor Study (REDS) Allogeneic Donor and Recipient (RADAR) repository. 20 This collection was organized between 2000 and 2003 by seven US blood centers. It links 13,201 donations, from 12,408 donors, with 3575 patients in eight California, Florida, Maryland, Michigan, Oklahoma, and Pennsylvania hospitals; these patients had cardiac, vascular, or orthopedic operations. The RADAR repository contains plasma samples from donors, and paired plasma samples that were collected from patients before or immediately after transfusion, and 6 to 12 months later.
MATERIALS AND METHODS

Patient-recipient and donation samples
The RADAR repository 20 21 The characterized research specimen was bile, containing approximately 9.8 log IU/mL of HEV subtype 2a, from a cynomolgus monkey that was experimentally infected with strain Mexico-14 in human feces; GenBank M74506 and KX578717 correspond to HEV in the fecal specimen.
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Testing algorithm for repository specimens
Our approach was intended to identify patients who had antibody evidence of HEV exposure during the pre-to posttransfusion sampling interval, and then HEV RNAcontaining donations that were likely sources of such exposure ( Fig. 1) . We use the term exposure, rather than infection because the latter term might imply degrees of HEV replication and HEV-associated disease that could not be determined.
Detection and semiquantitation of IgG anti-HEV
We assayed patients' plasma specimens by using a commercially available enzyme-linked immunosorbent assay (ELISA) (Wantai HEV-IgG ELISA , Beijing Wantai Biological Pharmacy Enterprise), generally following manufacturer's instructions. Minor modifications included reassaying selected patients' specimens, which had yielded posttransfusion IgG anti-HEV sample-to-cutoff values (S/CO post ) > 6.0, diluted 1:4 or 1:8 in phosphate-buffered saline, pH 7.0, with 1% wt/vol bovine serum albumin. By assaying such two-fold dilutions of the WHO Reference Reagent for HEV Antibody, we determined analytic sensitivity of the IgG anti-HEV ELISA to be 1 U/mL according to preassay concentration, or 0.091 U/mL in ELISA (Table S1 , available as supporting information in the online version of this paper). When a posttransfusion specimen was nonreactive for IgG anti-HEV, the corresponding pretransfusion sample was not tested, and the patient interpreted as not HEV exposed before or during the sampling interval. When a posttransfusion specimen was reactive, we tested the corresponding pretransfusion sample and compared results with those obtained earlier for posttransfusion specimens. We defined patients as having tentatively seroconverted when pretransfusion results were nonreactive or equivocal (S/CO pre <1.1), and possibly increased IgG anti-HEV concentration when S/CO post was at least 3.5-fold higher than S/CO pre of 1 or greater.
We then reassayed, on the same ELISA plate, each specimen pair that yielded such preliminary evidence of sampling interval exposure. Same-plate IgG anti-HEV Fig. 1 . Testing algorithm for patient-recipient and donation samples from the RADAR repository. We assayed posttransfusion specimens for IgG anti-HEV and, for those with reactive results, tested corresponding pretransfusion specimens in subsequent assay runs. Each specimen pair that yielded preliminary evidence of HEV exposure during the sampling interval, as manifested by seroconversion or by a 3.5-fold or greater increase in IgG anti-HEV S/CO value, was reassayed on a single ELISA plate. We then assayed for HEV RNA in donations that were linked to patients who had single-plate confirmed seroconversion or a fourfold or greater increase of IgG anti-HEV concentration. Finally, we determined and analyzed partial nucleotide sequences of any detected HEV RNA in donation samples.
results were used to identify 1) incident exposure, or seroconversion, defined as pretransfusion nonreactive (S/CO pre <1) and posttransfusion reactive; 2) reexposure, as both specimens reactive and posttransfusion concentration at least fourfold higher than before transfusion (S/CO post after fourfold dilution ≥ S/CO pre ); and 3) past exposure, as both specimens reactive and S/CO post after fourfold dilution less than or equal to S/CO pre or, without dilution, S/CO post less than 6.0 and less than four times S/CO pre . Our reexposure criterion was based on a linear and approximately 1:1 correlation between WHO U/mL and IgG anti-HEV S/CO ranging from 0.25 to 6.0 (Table S1 ).
Detection and quantitation of HEV RNA
We tested donation samples, identified as linked to patients who had serologic evidence of HEV exposure during the sampling interval, by using assays that are based on polymerase chain reaction (PCR) or transcription-mediated amplification (TMA).
To generate templates for reverse-transcription quantitative PCR (RT-qPCR) and for sequence analysis (below), we added approximately 4.7 log pfu of coliphage MS2 25 and 8 μg of yeast transfer RNA to 200 μL of plasma or reference material. We then purified RNA and DNA by using MagNA Pure LC Total Nucleic Acid Isolation-High Performance kits with the MagNA Pure LC 2.0 instrument, Roche Diagnostics), eluting into 100 μL of proprietary (Roche) buffer. We detected and quantified HEV RNA with a RT-qPCR assay that our Johns Hopkins Bloomberg School of Public Health (JHBSPH) laboratory implemented for environmental and plasma samples 26, 27 and then adapted to increase sensitivity and throughput. We mixed 5 μL of purified nucleic acids into a 20-μL reaction with a master mix product (VeriQuest Probe One-Step qRT-PCR Master Mix, Affymetrix/USB) and oligonucleotide sets for amplifying a highly conserved segment of the HEV genome 28 (primers, 500 nM; probe, 250 nM) and for MS2 25 (primers, 250 nM; probe, 125 nM; for sequences, see Table S2 , available as supporting information in the online version of this paper). RNAs were reverse transcribed and then amplified in a qPCR system (Applied Biosystems StepOnePlus Real-Time PCR system, Thermo Fisher Scientific) by incubating at 50 C for 15 minutes and 95 C for 10 minutes; and then 45 cycles of 95 C for 15 seconds, 55 C for 20 seconds, and 60 C for 20 seconds. The quantitation standard was cloned HEV cDNA, assayed as a 10-fold dilution series of concentrations between 0.5 log and 5.5 log copies/reaction. Samples that yielded an HEV threshold cycle (C T ) value of 38.0 or less were considered to be positive. Analytic sensitivity was 2.5 log IU/mL of plasma, or 0.5 log IU/reaction; 0.5 log 10 IU corresponded to 1.5 log 10 copies of cloned HEV cDNA.
To confirm selected RT-qPCR results, donation specimens were tested with a TMA-based assay (Procleix HEV, Hologic; and Grifols Diagnostic Solutions) that has a 95% detection probability of 0.90 log IU/mL. 16 This assay requires 0.7 mL of specimen for singulate testing; because the volume of many RADAR samples is extremely limited, selected samples were diluted as much as eightfold (i.e., 0.1 mL of sample with 0.7 mL of proprietary buffer).
Determination and analysis of HEV cDNA nucleotide sequences
We synthesized and then amplified HEV cDNA via nested PCR with primers that represent segments of HEV open reading frame (ORF) 1 and ORF2 [29] [30] [31] (Table S2; Ticehurst and Forman, unpublished data). Sanger sequence reads were generated from nested PCR products by using a genetic analyzer (3500 Genetic Analyzer, Applied Biosystems) and then base-called, trimmed to amplicon-length without primers, and assembled by computer software (Aligner version 8. (included with BioEdit). We initially constructed a partial-ORF1 tree by using 158 unique HEV reference sequences 35 and the approximate likelihood ratio test for branch assessment. 33 For clarity in this presentation, we remade the partial-ORF1 tree with 32 taxa, 27 of which represent consensus reference strains for the four human HEV genotypes and a genotype 5 representative as outgroup, 36 plus three other well-characterized human strains. 35 For this tree, we statistically assessed branches by bootstrapping with 100 resamplings, outgroup-rendered the tree with computer software (TreeView version 1.6.6; for availability, see Web Resources), and annotated it by using presentation software (PowerPoint 2016, Microsoft). We similarly generated trees from partial ORF2 sequences (not shown). We also compared nucleotide sequences representing our JHBSPH laboratory's HEV strains to determine if those representing the RADAR donation are unique; that is, not the result of contamination.
RESULTS
IgG anti-HEV in single and paired specimens from RADAR patient-recipients 
Detection and analysis of HEV RNA
The 59 RADAR patients who had evidence of HEV exposure were linked to 257 donations from 257 donors, all of which were assayed for HEV RNA by RT-qPCR. Fifteen of 257 (5.8%) were positive: one yielded a C T of 26.9, the 14 other C T values ranged between 33.9 and 37.5. Seventeen of these 257 donations, including 14 RT-qPCR positives and 1 that yielded an invalid result (MS2 internal control not detected), were also assayed by using the Procleix HEV assay. One (0.008% of 13,201 linked donations) RT-qPCR-positive was confirmed, that for which C T was 26.9. We also RT-qPCR assayed remaining plasma (50 μL before transfusion, 200 μL after transfusion) from the recipient of the HEV RNAcontaining donation; neither had detectable HEV RNA. By RT-qPCR, the HEV RNA-confirmed specimen contained 5.5 log 10 IU per mL of plasma. This RNA phylogenetically represents HEV genotype 3, clade 3abchij, 37 Characteristics of the donation with detectable HEV RNA and selected patient-recipients
The HEV RNA-containing donation was from an individual who made a single donation that was documented in the RADAR archive. This donation was transfused as RBCs to one patient who received three other RBC units, each from one donor. This patient's IgG anti-HEV concentration increased more than eightfold after transfusion; that is, the S/CO of a 1:8 diluted posttransfusion sample was greater than the S/CO of a neat pretransfusion sample ( Table 2 ). As noted above, HEV RNA was not detected in either of this patient's specimens. Nine of the other 58 IgG anti-HEV seroconversions and reexposures were linked to an HEV RNA-negative donation that was also linked to a second recipient. In two such instances, both recipients seroconverted. Otherwise, the second recipient did not have evidence of exposure during the sampling interval: both specimens were reactive for IgG anti-HEV without a pre-to posttransfusion increase, or both were nonreactive (data not shown).
It is not known if any donor or patient developed symptoms or signs of HEV-associated disease or if patients had foodborne or other types of exposure to HEV because repository data do not contain such information about RADAR subjects. Certain demographic characteristics of RADAR donors and patient-recipients are available; Bio-LINCC and NHLBI do not allow such characteristics in publications, however, because of privacy concerns.
DISCUSSION
To our knowledge, our report provides the first documentation of probable HEV transmission via transfusion in the United States, from an HEV RNA-containing donation to a patient who had antibody evidence of HEV exposure. Our data are suggestive of reexposure because the patient had IgG anti-HEV that increased in concentration after transfusion; IgG anti-HEV evidence of HEV reexposure has been reported. 38 Because the RADAR database does not include subjects' clinical data, we cannot determine if this patient-recipient developed any HEV-associated illness. Pathogenic association with either clade 3abchij, with which the RADAR-donation HEV RNA phylogenetically grouped (Fig. 2) , or clade To detect HEV transmission that was temporally associated with transfusion, our strategy was to evaluate all possible incident and secondary exposures by assaying linked donations for HEV RNA (Fig. 1) . By testing paired recipient specimens for IgG anti-HEV, we identified patients who had antibody evidence of exposure during the pre-to posttransfusion interval, thereby reducing the number of donations to assay for HEV RNA. The 59 identified HEV exposures are based on same-plate ELISA testing that reproduced earlier results from separate runs in which the identity of specimen pairs was blinded.
One cannot unambiguously conclude that a blood product is the source of HEV transmission unless the donor is determined to circulate infectious HEV, which most likely would require inoculation of a susceptible primate. While more definitive evidence of transfusion transmission would include a donation and linked recipient with identical or nearly identical HEV RNAs, it is extremely unlikely that RADAR posttransfusion samples, like others collected from immunocompetent patients at least 6 months after exposure, 12,39-41 would contain HEV RNA.
We also cannot rule out a temporal association, without transmission, between the HEV RNA-containing donation and linked patient-recipient: better evidence would include detectable or increased anti-HEV in posttransfusion specimens collected sooner than those in the RADAR repository. Transfusion transmission accounts for a minority of all HEV infections except possibly those among highly transfusion-dependent patients. Based on an estimated 0.2% annual HEV incidence in the United Kingdom, investigators there estimated that the ratio of foodborne to transfusion-acquired HEV was approximately 13:1. 42 This ratio may be higher in the United States because, among the 59 incident exposures and reexposures that we identified, only one could be associated with an HEV RNAcontaining donation. We may have underestimated transfusion transmission risk, however, because RADAR patients also received 11,141 blood components from donors who were not enrolled in the study and therefore could not be linked to HEV-exposed patient-recipients and screened for HEV RNA. 20 In addition,
RADAR patients who died less than 6 months after transfusion were not studied because posttransfusion specimens could not be collected. Patients who contributed paired specimens were generally immunocompetent, but others who might have been at higher risk of HEV infection (e.g., organ transplant recipients) were not included. 20 We also may have underdetected HEV RNA-containing donations because the confirmatory assay for HEV RNA was considerably more sensitive than that we used for initial HEV RNA detection. We encountered other limitations that are worth noting. First, our RT-qPCR assay yielded positive results that failed confirmation via the more sensitive TMA-based assay, and we generated HEV sequences only from the TMAconfirmed donation and two HEV RNA reference materials. While it is very unlikely that these false positives resulted from cross contamination, several pertinent samples yielded human DNA after nested PCR with primers for HEV ORF1 or ORF2 (data not shown). Computer-assisted searches did not reveal high identity between GenBank human sequences and our RT-qPCR oligonucleotides for HEV ORF3 and coliphage MS2. Other groups have noted failure to reproduce initial HEV RNA detection 16 or have successfully coamplified HEV and MS2 cDNAs. 43 Second, we attempted to generate IgM anti-HEV data with a commercial μ-capture 36 and 3ra that primarily represents rabbits and for which there is one reported human-strain sequence that includes the pertinent ORF1 segment. 57, 58 Boxed "USA human c2001 RADAR donor" designates sequence from this study. Largest numerals and brackets indicate genotypes; numeral 3 followed by letters indicate proposed monophyletic groups. 37 Bar indicates genetic distance. [Color figure can be viewed at wileyonlinelibrary.com]
ELISA and an analogous approach to that for detecting IgG anti-HEV. The overall frequency of IgM anti-HEV reactivity was higher than in other studies, and most reactive results were implausible or uninterpretable; some such reactivity may have been caused by nonspecific binding between captured IgM or other specimen material and reagent HEV ORF2 protein (data not shown). Furthermore, samplecollection timing made it impossible to determine if any patient developed IgM anti-HEV soon after transfusion and then "seroreverted" to undetectable when the posttransfusion specimen was collected. While posttransfusion IgM and IgG anti-HEV might be considered as more definitive evidence for exposure, assays for IgM antiviral antibodies are typically configured to yield predominantly nonreactive results by 6 months into convalescence. Third, although interrun repeatability was a requirement for incident-or reexposure categorization, we cannot exclude the possibility of false-positive IgG anti-HEV results because we did not independently verify reactivity (e.g., via western blot immunoassay) and our 31% frequency of IgG anti-HEV reactivity is high. Noting that RADAR patient-recipients were older (91% and 74% at least 50 and 60 years old, respectively) and predominantly male (54%), 20 our IgG anti-HEV frequency is consistent with several of those reported for older US subpopulations 18, 19, 44, 45 (see discussion below about prevalence).
The only other HEV study of US recipients and linked donors, by Xu et al., 18 investigated 362 patients near or in Washington, D.C. (NIH CC, Suburban Hospital, and Children's National Medical Center), starting in 2001. Two patient-recipients, including one who received an HEV RNA-containing and a "high-titer" anti-HEV product shortly before death, became reactive for IgG anti-HEV, but the authors concluded that neither patient had a transfusion-associated exposure to HEV. Another publication reported the results of retrospectively assaying cryopreserved specimens that were collected during the 1960s, prior to routine donor screening for viral markers, from 66 NIH CC cardiac surgery patients who developed posttransfusion hepatitis: 4 (6%), 20 (31%), and 1 (2%), respectively, were infected with hepatitis B virus, hepatitis C virus, and HEV. 46 It is highly likely that many transfusion transmissions of HEV have gone unrecognized in the United States. Linking donations to American recipients has been difficult because most blood product collection, processing, and distribution are centralized, and the products are often transfused after a substantial interval. Also, foodborne transmission of HEV genotype 3 is likely to be more common than infection from a transfusion in the United States, a likelihood with which our data are consistent. In addition, the lack of FDA-licensed assays for detecting serologic or virologic evidence of HEV infection, as well as US clinicians' unfamiliarity with hepatitis E and extrahepatic manifestations of HEV infection, 47 are important barriers to diagnosis.
However, large population-based surveys have documented high anti-HEV prevalence in the general US population. A study by Kuniholm et ), for which testing is currently performed; the latter frequencies are 41 to 240 times higher than corresponding infection frequencies (1, 0.83, and 0.67 per million 16 ). It is not known if US infection and illness frequencies for HEV are comparable, for example, to those reported for the southeastern United Kingdom, where 18 of 43 recipients of HEV RNA-containing blood products became infected, among whom 5 had elevated serum concentrations of alanine aminotransferase, including 1 with clinically apparent hepatitis, and 10 developed prolonged or persistent infection. 8 Health economic analysis, similar to that performed for the Netherlands, 55 could be important for the United States;
however, the data on HEV transmission in the United States are too scarce to do such an analysis at present.
In conclusion, we detected one case of likely transfusion transmission of HEV among a population of 3384 transfused patients in the United States. These recipients were exposed to approximately 25,000 blood components, among which 13,800 were from linked donations. 20 We were able to identify this case even though the RADAR population was much smaller than the UK linked study population. 8 Our study's source donor, who likely transmitted HEV, had an HEV RNA plasma concentration of 5.5 log IU/mL. This level of HEV RNA was consistently associated with HEV transmission from donors in the large UK study 8 and is much greater than those of the two HEV RNA positive donors in the ARC study 16 or the three in a recent study of US plasma donors. 17 To our knowledge, our report documents for the first time that the risk of transfusiontransmitted HEV probably exists in the United States. Further quantifying this risk, and potentially developing a strategy to prevent HEV transfusion transmission to US patients at high risk of complicated infections, should be priorities.
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